Three patients administered daratumumab in combination with bortezomib and dexamethasone prior to ASCT showed a clinical response and a decrease in VEGF compared to the previous patient.[25] Thirteen cases of M protein-negative POEMS syndrome have been reported in the literature: 12 patients were treated with ASCT, melphalan-based regimens, and lenalidomide/thalidomide-containing regimens, all of which achieved clinical improvement.[12] In our case, complete normalization of serum VEGF levels was achieved after antiplasma cell therapy. The gene discussed is VEGFA; the disease is POEMS syndrome.